Compare Illumina, Inc. (ILMN) vs Wells Fargo & Co (WFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Wells Fargo & Co — how do they compare? Illumina, Inc. trades at $189.79 (market cap $27.94B), while Wells Fargo & Co trades at $86.93 (market cap $261.45B). The key difference: Wells Fargo & Co is far larger — about 9.4× Illumina, Inc.'s market cap, and Wells Fargo & Co pays a 2.09% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| ILMN | WFC | |
|---|---|---|
Market Cap | $27.94B | $261.45B |
Sector | Health | Financials |
52-Week High | $194.33 | $96.40 |
52-Week Low | $91.00 | $73.42 |
Enterprise Value | $29.33B | — |
Dividend Yield | — | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $185.36, down 0.69% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 19.42% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and upcoming Q2 2026 earnings on July 30.
Outlook remains positive with 51% analyst buy ratings, though the current price exceeds the $178 consensus target. Key risks include competitive pressure from Roche's new sequencer and China market weakness. Earnings growth and cost control initiatives support upside potential, but valuation multiples suggest limited near-term appreciation.
Wells Fargo (WFC) trades at $86.3, down 1.4% on the day, with a bullish technical outlook from moving averages and a consensus analyst price target of $97.36. The bank reported strong Q2 2026 earnings, beating EPS estimates with $1.96 actual versus $1.73 expected, driven by net interest income and fee growth. Revenue trends show steady growth from $83.7B in 2025 to a projected $87.0B in 2026, with net income margins improving to 25.97%. Recent news highlights AI investments in wealth management and a healthy investment banking pipeline.
The outlook for WFC is positive, supported by earnings momentum, dividend payments, and analyst upgrades. Key opportunities include continued revenue growth and efficiency gains post-asset cap removal. Risks involve net interest margin pressure, expense management challenges, and macroeconomic sensitivity. Institutional sentiment is mixed but leans bullish, with 45% of analysts rating it a buy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Wells Fargo & Co
Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets. The company is split into four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the U.S.
Read more on WFC →
